Fibrosarcoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fibrosarcoma – Pipeline Review, H2 2016’, provides an overview of the Fibrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma

The report reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Fibrosarcoma therapeutics and enlists all their major and minor projects

The report assesses Fibrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Fibrosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advanced Proteome Therapeutics Corporation

Advenchen Laboratories, LLC

Daiichi Sankyo Company, Limited

Elsalys Biotech SAS

Millennium Pharmaceuticals Inc

Novartis AG

Rigontec GmbH

Sumitomo Dainippon Pharma Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fibrosarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Fibrosarcoma - Overview 8

Pipeline Products for Fibrosarcoma - Comparative Analysis 9

Fibrosarcoma - Therapeutics under Development by Companies 10

Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 11

Fibrosarcoma - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Fibrosarcoma - Products under Development by Companies 15

Fibrosarcoma - Products under Investigation by Universities/Institutes 16

Fibrosarcoma - Companies Involved in Therapeutics Development 17

Advanced Proteome Therapeutics Corporation 17

Advenchen Laboratories, LLC 18

Daiichi Sankyo Company, Limited 19

Elsalys Biotech SAS 20

Millennium Pharmaceuticals Inc 21

Novartis AG 22

Rigontec GmbH 23

Sumitomo Dainippon Pharma Co., Ltd. 24

Fibrosarcoma - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

AL-3818 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

APC-103 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Cellular Immunotherapy for Oncology - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

DSR-6434 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

everolimus - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ImOl-100 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

LK-3 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

MAT-303 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

PLX-7486 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

sapanisertib - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SEN-461 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SOM-0777 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Fibrosarcoma - Dormant Projects 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for Fibrosarcoma, H2 2016 8

Number of Products under Development for Fibrosarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Fibrosarcoma – Pipeline by Advanced Proteome Therapeutics Corporation, H2 2016 17

Fibrosarcoma – Pipeline by Advenchen Laboratories, LLC, H2 2016 18

Fibrosarcoma – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19

Fibrosarcoma – Pipeline by Elsalys Biotech SAS, H2 2016 20

Fibrosarcoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21

Fibrosarcoma – Pipeline by Novartis AG, H2 2016 22

Fibrosarcoma – Pipeline by Rigontec GmbH, H2 2016 23

Fibrosarcoma – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Fibrosarcoma – Dormant Projects, H2 2016 62

List of Figures

List of Figures

Number of Products under Development for Fibrosarcoma, H2 2016 8

Number of Products under Development for Fibrosarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports